Edwards Lifesciences Corp
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net income | $1,069.4 | $4,169.7 | $1,399.4 |
| Other comprehensive income (loss), net of tax (Note 17): | |||
| Foreign currency translation adjustments | 45.6 | (59.6) | 4.3 |
| Unrealized (loss) gain on hedges | (47.5) | 37.0 | (23.1) |
| Unrealized pension credits (costs) | 4.9 | 0.1 | (9.9) |
| Unrealized gain on available-for-sale investments | 3.2 | 20.8 | 40.8 |
| Other comprehensive income (loss), net of tax | 6.2 | (1.7) | 12.1 |
| Comprehensive income | 1,075.6 | 4,168.0 | 1,411.5 |
| Less: Comprehensive loss attributable to noncontrolling interest | (4.1) | (4.9) | (3.0) |
| Comprehensive income attributable to Edwards Lifesciences Corporation | $1,079.7 | $4,172.9 | $1,414.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.